Boston—Body mass index (BMI) is an independent predictor of metastasis and prostate cancer mortality after radical prostatectomy, according to results from a large, long-term single-institution study.
Findings from the research also suggest that obesity may be a factor to consider for men with prostate cancer deciding between active surveillance and definitive treatment. The findings were presented at the 2017 AUA annual meeting in Boston.
Conducted using data from Mayo Clinic’s prospectively maintained radical prostatectomy registry, the study included 18,039 men with non-metastatic disease who underwent radical prostatectomy in the years 1987 to 2013 and who had information on BMI and received no treatment prior to surgery. Median follow-up after surgery was 9.3 years.
The patients were divided into four groups based on BMI: <25 kg/m2 (normal), 25-29.0 kg/m2 (overweight), 30-34.9 kg/m2 (obesity class 1), and >35 kg/m2 (obesity class ≥2). Of the 18,039 men included in the study, nearly 5,000 were obese, of whom 3,936 had a BMI of 30-34.9 kg/m2 and 1,016 had a BMI ≥35 kg/m2.
Findings from Kaplan-Meier analysis showed rates of metastasis and prostate cancer mortality were higher in men with BMI 30-34.9 kg/m2 and ≥35 kg/m2 compared with the normal BMI group. The associations between BMI and these outcomes were confirmed on multivariable Cox regression analysis controlling for potential confounding factors. Compared with the reference group, the odds of metastasis and prostate cancer mortality were each increased about 1.3-fold in men with a BMI 30-34.9 kg/m2, and they were increased 1.4- and 1.6-fold, respectively, in the men whose BMI was >35 kg/m2.
“An effect of obesity on risk of recurrence after radical prostatectomy has been debated because of conflicting data. Compared with previous investigations, however, our study had greater power to parse out potential associations because it included a much larger cohort of obese men and had longer follow-up,” said Vidit Sharma, MD, urology resident at Mayo Clinic, Rochester, MN, who worked on the study with principal investigator R. Jeffrey Karnes, MD, and colleagues.
“Our findings are also consistent with those of a recent meta-analysis including patients undergoing various forms of treatment for prostate cancer that reported associations between obesity and both more aggressive disease and prostate cancer-specific mortality (Oncol Lett 2015; 9:1307-12),” Dr. Karnes told Urology Times.